Effect of celecoxib on inhibiting tumor repopulation during radiotherapy in human FaDu squamous cell carcinoma

Wspolczesna Onkologia

Volumn 18, Issue 4, 2014, Pages 260-267

  Yang, Jia ^a,b   Yue, Jin Bo ^b   Liu, Jing ^c   Sun, Xin Dong ^b   Hu, Xu Dong ^a   Sun, Ju Jie ^b   Li, Yu Hui ^b   Yu, Jin Ming ^b  

^a UNIVERSITY OF JINAN   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cyclooxygenase (COX) 2 inhibitor; Fractionated radiotherapy; Tumor repopulation

Indexed keywords

BROXURIDINE; CASPASE 3; CELECOXIB; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BALB/C NUDE MOUSE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FADU SQUAMOUS CELL CARCINOMA; FEMALE; HINDLIMB; HUMAN; IMMUNOHISTOCHEMISTRY; IRRADIATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 84907197684     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.43932     Document Type: Article

References (25)

1. Baumann M, Dörr W, Petersen C, Krause M. Repopulation during fractionated radiotherapy: much has been learned, even more is open. Int J Radiat Biol 2003; 79: 465-7.
2. Fenwick JD, Pardo-Montero J, Nahum AE, Malik ZI. Impact of schedule duration on head and neck radiotherapy: accelerated tumor repopulation versus compensatory mucosal proliferation. Int J Radiat Oncol Biol Phys 2012; 82: 1021-30.
3. Hesselmann S, Lindel K, Horn K, Könemann S, Schuck A, Willich N, Rübe C. Time factor and repopulation during fractionated radiotherapy. Comparison between two xenografted human squamous cell carcinoma. Strahlenther Onkol 2003; 179: 38-44.
4. Bütof R, Dubrovska A, Baumann M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 2013; 108: 388-96.
5. Petersen C, Zips D, Krause M, Schöne K, Eicheler W, Hoinkis C, Thames HD, Baumann M. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001; 51: 483-93.
6. Petersen C, Eicheler W, Frömmel A, Krause M, Balschukat S, Zips D, Baumann M. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003; 79: 469-77.
7. Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 2008; 70: 203-12.
8. Wang AH, Tian XY, Yu JJ, Mi JQ, Liu H, Wang RF. Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression. J Int Med Res 2012; 40: 56-66.
9. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cycloox-ygenase- 2 inhibitor. Clin Cancer Res 2000; 6: 2513-20.
10. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31.
11. Yang YL, Xu KL, Zhou Y, Gao X, Chen LR. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J (Engl) 2012; 125: 450-4.
12. Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. Clin Lung Cancer 2011; 12: 125-30.
13. Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, et al. Efficacy and safety of concurrent chemoradiation with weekly cis-platin +/- low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial. J Cancer Res Ther 2011; 7: 442-7.
14. Xue WP, Bai SM, Luo M, Bi ZF, Liu YM, Wu SK. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011; 47: 753-7.
15. Quidville V, Segond N, Tebbi A, Cohen R, Jullienne A, Lepoivre M, Lausson S. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid 2009; 19: 613-21.
16. Kim YY, Lee EJ, Kim YK, Kim SM, Park JY, Myoung H, Kim MJ. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells 2010; 29: 185-194.
17. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 2003; 9: 4324-31.
18. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 2006; 12: 314-20.
19. Schmidt-Ullrich RK, Contessa JN, Dent P, Mikkelsen RB, Valerie K, Reardon DB, Bowers G, Lin PS. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 1999; 7: 321-30.
20. Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003; 9: 1302-6.
21. Bucci B, Misiti S, Cannizzaro A, et al. Fractionated ionizing radiation exposure induces apoptosis through caspase-3 activation and reactive oxygen species generation. Anticancer Res 2006; 26: 4549-57.
22. de Heer P, de Bruin EC, Klein-Kranenbarg E, et al. Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res 2007; 13: 5810-15.
23. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in nonsmall cell lung tumor xenograft model. Clin Cancer Res 2009; 15: 6096-105.
24. Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17: 860-6.
25. Kim KW, Moretti L, Lu B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS One 2008; 3: e2275.